Amphastar Pharmaceuticals to Offer $300 Million in Convertible Senior Notes


Amphastar Pharmaceuticals saw a 9% decrease in its shares, dropping to $46.97, following the announcement of its plans to offer $300 million of convertible senior notes due 2029 in a private placement.

Positive Growth for Amphastar

Despite the recent decline, it is worth noting that Amphastar Pharmaceuticals experienced a significant surge in its stock price, reaching a 52-week high of $67.66 on August 9. Over the past year, the shares have increased by an impressive 62%.

Additional Option for Purchasers

As part of the offering, Amphastar intends to grant the initial purchasers of the notes an option to purchase up to an additional $45 million in notes.

Key Details of the Notes

The convertible senior notes will represent general senior unsecured obligations of Amphastar and will accrue interest payable semi-annually in arrears. The specific interest rate, initial conversion rate, and other terms will be determined at the time of pricing for the offering.

Allocation of Proceeds

Amphastar plans to utilize $200 million from the offering to repay its existing term loan borrowings. Furthermore, they anticipate using up to $50 million to repurchase their own stock. The remaining proceeds will be allocated towards general corporate purposes.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Huawei’s Mate 60 Pro Launch Could Impact Apple’s Business in China

Next Post

Enphase Energy Stock Faces Uphill Battle in Residential Solar Industry

Related Posts